10-Q: Hestia Insight Reports Significant Q1 Loss Amidst Zero Revenue and Going Concern Warning

Hestia Insight Inc. reported a substantial net loss of $392,295 for the first quarter ended February 28, 2025, with no revenue generated, raising significant doubt about its ability to continue as a going concern.

Summary

• Hestia Insight Inc. reported a net loss of $392,295 for the three months ended February 28, 2025, a significant increase from the $24,699 net loss in the prior year period.
• The company generated no revenue for the quarter ended February 28, 2025, compared to $38,000 in consulting revenue for the same period in 2024.
• Operating expenses increased to $110,669 for the current quarter, up from $72,851 in the prior year, primarily driven by a $55,508 increase in other general and administrative expenses.
• A substantial change in the fair value of investments resulted in a $259,500 loss for the current quarter, contributing significantly to the increased net loss.
• The company's cash and cash equivalents decreased to $37,960 as of February 28, 2025, from $41,163 as of November 30, 2024.
• Accumulated deficits grew to $506,617 as of February 28, 2025, from $114,323 as of November 30, 2024.
• Total liabilities increased to $247,139 as of February 28, 2025, from $206,306 as of November 30, 2024, partly due to additional related party notes payable.
• The company continues to operate as a development stage enterprise, dependent on debt and equity financing to fund operations, and faces substantial doubt about its ability to continue as a going concern.
• Stock-based compensation recognized for the quarter was $60,000, related to the vesting of issued stock options to management and directors.

Sentiment

Score: 1

Explanation: The sentiment is extremely negative due to zero revenue, a significantly widened net loss, a substantial increase in accumulated deficits, a critical going concern warning, and ineffective internal controls. The company's financial viability is explicitly questioned in the filing.

Positives

• Cash used in operating activities decreased to $36,047 for the three months ended February 28, 2025, compared to $46,034 in the prior year period, indicating a slight improvement in operational cash burn.
• Professional fees decreased by $17,169, or 40%, for the three months ended February 28, 2025, compared to the prior year, reflecting a current emphasis on reducing costs.

Negatives

• The company reported zero revenue for the three months ended February 28, 2025, a complete cessation from the $38,000 in consulting revenue generated in the prior year period.
• Net loss significantly widened to $392,295 for the current quarter, compared to $24,699 in the same period last year, primarily due to a large unrealized loss on investments.
• A $259,500 change in the fair value of investments contributed heavily to the increased net loss.
• Accumulated deficits increased substantially to $506,617 as of February 28, 2025, from $114,323 as of November 30, 2024.
• The company's cash balance decreased, and total liabilities increased, indicating a deteriorating financial position.
• The company's disclosure controls and procedures were deemed ineffective as of February 29, 2024, due to limited resources and employees.

Risks

• The company has not yet established an ongoing source of revenues sufficient to cover its operating costs and is dependent on debt and equity financing to fund its operations, raising substantial doubt about its ability to continue as a going concern.
• There is no assurance that the company will be able to raise additional equity capital or be successful in the development and commercialization of its investments and services.
• The company owns no patents and relies on trade secrets, confidential information, and trademarks, posing a risk to adequately protecting its intellectual property rights.
• The healthcare industry is highly regulated and subject to rapid changes, which could create unexpected liabilities, additional costs, or restrict operations.
• The company's limited resources and number of employees have led to ineffective disclosure controls and procedures.
• Future financing transactions, if successful, may lead to significant dilution for existing stockholders or new equity securities may have senior rights, preferences, or privileges.
• The inability to obtain additional capital may restrict the company's ability to grow and could force it to cease operations.

Future Outlook

The company's future operations are dependent on its ability to secure additional financing, as current cash is insufficient to satisfy cash requirements under present operating expectations. Management is making efforts to raise additional funding, but there is no assurance that such financing will be available on satisfactory terms. The company intends to pursue strategic acquisitions, licensing, or joint ventures in the healthcare and biotech sectors and will also consider investing in certain technologies. They expect professional fees to remain significant due to public company reporting requirements and corporate governance costs.

Management Comments

• "The limited amount of revenue was due to our current emphasis on planning and preparation for our future revenue."
• "Management of the Company is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect."
• "While management of the Company believes that it will be successful in its capital formation and planned operating activities, there can be no assurance that we will be able to raise additional equity capital or be successful in the development and commercialization of the investments and services it develops or enters into collaboration agreements thereon."
• "Ultimately, the Company will need to achieve profitable operations in order to continue as a going concern."
• "We expect professional fees to be significant as we incur significant costs associated with our public company reporting requirements, and costs associated with newly applicable corporate governance requirements, including requirements under the Sarbanes-Oxley Act of 2002 and other rules implemented by the Securities and Exchange Commission."
• "Our ability to continue as a going concern is dependent upon our ability to carry out our business plan, achieve profitable operations, obtain additional working capital funds from our significant shareholders, and or through debt and equity financing."
• "We estimate that based on current plans and assumptions, that our available cash will be insufficient to satisfy our cash requirements under our present operating expectations."
• "To date, we have not considered this alternative [ceasing operations], nor do we view it as a likely occurrence."

Industry Context

Hestia Insight operates in the highly regulated healthcare and biotech sectors, focusing on strategic consulting, medical supply sales, and smart vending solutions. The company aims to acquire and develop emerging growth companies with unique sciences and technologies. Its competitive advantage is stated to be its focus on small and micro-cap companies with limited access to growth capital, leveraging a global business network. However, the company faces competition from various advisory firms and direct service providers in its target markets. The broader industry context suggests a need for significant capital and robust intellectual property, areas where Hestia Insight currently shows weaknesses (no patents, reliance on external financing).

Comparison to Industry Standards

• NA The document does not provide specific comparable companies, projects, or results to assess against global benchmarks. The company's current financial performance (zero revenue, significant losses, going concern warning) is far below typical industry standards for sustainable operations.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings that would have a material adverse effect on its business, operating results, financial condition, or cash flows.

Related Party Transactions

• On January 15, 2024, the Company entered into a $50,000 note payable to ECL Capital Partners Corp, which has been extended until January 15, 2026, with interest at 6.00% per annum.
• In May 2024, an additional short-term loan of $3,931 was received from Mr. Edward C. Lee, bearing no interest.
• On August 25, 2024, the Company entered into a $25,000 note payable to ECL Capital Partners Corp, to be repaid by August 24, 2025, with interest at 6.00% per annum.
• On February 17, 2025, the Company entered into a $25,000 note payable to ECL Capital Partners Corp, to be repaid by February 17, 2026, with interest at 6.00% per annum.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity raises and substantial risk of losing their entire investment due to the going concern warning and ongoing losses.
• **Employees**: The company has only three employees and relies on independent contractors, suggesting limited operational scale and potential job insecurity given the financial challenges.
• **Creditors**: Related party creditors (ECL Capital Partners Corp, Edward C. Lee) are providing ongoing financing, but the company's going concern status indicates elevated risk for all creditors.
• **Customers**: The company generated no revenue in the current quarter, implying a lack of active customer engagement or significant service delivery in its consulting and vending segments.

Next Steps

• Management is making efforts to raise additional funding to support operations.
• The company intends to pursue strategic acquisitions, licensing, or joint ventures in the healthcare and biotech sectors.
• The company will continue to file Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, and Current Reports on Form 8-K with the SEC.

Key Dates

Recommendation

Keywords

Healthcare, Biotech, Vending machines, Consulting services, SEC filing, 10-Q, Financial results, Net loss, Going concern, Capital raise, Related party loans, Investment losses, Corporate governance, Risk factors